About Mural Oncology plc
https://www.muraloncology.comMural Oncology Plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.
CEO
Caroline J. Loew
Compensation Summary
(Year )
ETFs Holding This Stock
Summary
Showing Top 1 of 1
Most Recent Analyst Grades
Grade Summary
Showing Top 2 of 2
Price Target
Institutional Ownership
ORBIMED ADVISORS LLC
Shares:588.8K
Value:$1.2M
NEWTYN MANAGEMENT, LLC
Shares:522.92K
Value:$1.07M
OMERS ADMINISTRATION CORP
Shares:511K
Value:$1.04M
Summary
Showing Top 3 of 66
About Mural Oncology plc
https://www.muraloncology.comMural Oncology Plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $3.97M ▼ | $-3.71M ▲ | 0% | $-0.21 ▲ | $-2.91M ▲ |
| Q2-2025 | $0 | $30.26M ▼ | $-47.98M ▼ | 0% | $-2.78 ▼ | $-46.88M ▼ |
| Q1-2025 | $0 | $34.38M ▼ | $-33.14M ▲ | 0% | $-1.93 ▲ | $-33.53M ▲ |
| Q4-2024 | $0 | $35.85M ▲ | $-34.27M ▼ | 0% | $-2.01 ▼ | $-34.99M ▼ |
| Q3-2024 | $0 | $34.1M | $-31.76M | 0% | $-1.87 | $-33.2M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $58.87M ▼ | $65.76M ▼ | $10.57M ▼ | $55.19M ▼ |
| Q2-2025 | $77.09M ▼ | $87.56M ▼ | $28.77M ▲ | $58.78M ▼ |
| Q1-2025 | $107.68M ▼ | $132.08M ▼ | $24.19M ▼ | $107.89M ▼ |
| Q4-2024 | $144.38M ▼ | $169.39M ▼ | $28.89M ▼ | $140.5M ▼ |
| Q3-2024 | $175.5M | $203.27M | $29.13M | $174.14M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-3.71M ▲ | $-18.48M ▲ | $0 ▼ | $0 | $-18.48M ▲ | $-18.48M ▲ |
| Q2-2025 | $-47.98M ▼ | $-31.36M ▲ | $1.77M ▼ | $0 ▼ | $-29.59M ▼ | $-31.37M ▲ |
| Q1-2025 | $-33.14M ▲ | $-36.8M ▼ | $27.99M ▼ | $28K ▲ | $-8.78M ▼ | $-36.81M ▼ |
| Q4-2024 | $-34.27M ▼ | $-31.77M ▼ | $36.21M ▲ | $0 ▼ | $4.44M ▲ | $-31.79M ▼ |
| Q3-2024 | $-31.76M | $-30.08M | $19.31M | $196K | $-10.57M | $-30.09M |
CEO
Caroline J. Loew
Compensation Summary
(Year )
ETFs Holding This Stock
Summary
Showing Top 1 of 1
Most Recent Analyst Grades
Grade Summary
Showing Top 2 of 2
Price Target
Institutional Ownership
ORBIMED ADVISORS LLC
Shares:588.8K
Value:$1.2M
NEWTYN MANAGEMENT, LLC
Shares:522.92K
Value:$1.07M
OMERS ADMINISTRATION CORP
Shares:511K
Value:$1.04M
Summary
Showing Top 3 of 66